Skip to content
Parakho

Zim Laboratories Ltd

NSE ZIMLABBSE 541400zimlab.in

Q1 FY27, unaudited

Revenue
₹94.18 Cr
Profit after tax
₹-4.02 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations94.18+31.25%374.40
Other income0.99−32.78%11.38
Total income95.17+29.96%385.78
Employee benefit expense19.18+31.28%63.90
Finance costs3.64+10.29%13.20
Depreciation & amortisation5.37+10.46%19.98
Total expenses100.74+33.15%377.57
Profit before tax-5.57−129.15%8.21
Tax expense-1.56−179.30%2.37
Profit after tax-4.02−114.25%5.84
Total comprehensive income-3.65−150.52%7.94
Earnings per share
Earnings per share, basic₹-0.75₹1.19
Earnings per share, diluted₹-0.75₹1.19

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — unaudited, from the company’s filing with NSE. Source

Q1 FY27 results for every company Parakho holds

Earnings call

Q4 FY26

Zim Laboratories reported full year FY26 total operating income of approximately INR 3,744 million, broadly flat versus FY25, which management attributed to an estimated INR 20-25 crore revenue impact from MENA geopolitical disruption and continued EU GMP related constraints on the regulated pipeline. The company underwent an EU GMP re-inspection by German and Portuguese authorities from May 4-7, 2026, and management said the CAPA implementation is substantially complete with a positive outcome expected. Q4 FY26 EBITDA margin was approximately 12.7% and full year PAT stood at INR 58 million, with exports contributing approximately 82% of quarterly operating income.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote.

Read the full summary

Filings

12 shown · 51 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 08 Oct 2026.